Key result
Dabigatran maintains low stroke incidence at ~0.7 per 100 person-years in new-onset NVAF.
Why the study?
The safety and efficacy of dabigatran in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke needed to be established in a multinational setting.
Observational (n=15,308)
Yes
NOACs have been highly adopted in clinical practice for nonvalvular AF, surpassing VKAs, though a large proportion of patients remain undertreated globally.
Answers are grounded in this paper and cite their sources.
Baseline characteristics in GLORIA-AF Phase II reflect early NOAC adoption; leaves open long-term safety questions in new AF.
Background: The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF)is a multinational, prospective, 3-phase study to establish the safety and efficacy of dabigatran in patients with newly diagnosednonvalvular atrial fibrillation at risk of stroke. Phase II began when dabigatran, the first non-vitamin K antagonist oral anticoagulant(NOAC) became available.Objectives: The aim of this registry was to describe Phase II baseline clinical data in the general population and the 2-year follow-upof patients treated with dabigatran.Methods: Among 15,644 patients enrolled in the study, 15,308 were eligible and 4,873 received dabigatran. Atrial fibrillation characteristics,follow-up findings and concomitant diseases were recorded and analyzed using descriptive statistics.Results: Forty-five percent of eligible patients were women and median age was 71.0 years (interquartile range: 64-78 years). Patientswere from Europe (47.9%), North America (22.2%), Asia (20.1%), Latin America (6.0%), and the Middle East/Africa (3.9%).Most of them had high risk for stroke (CHA2DS2-VASc score ≥2; 86.1%) and 13.9% had moderate risk (CHA2DS2-VASc score=1). In80.3% of cases, patients received oral anticoagulants: 47.9% NOACs and 32.4% vitamin K antagonists (VKAs); 12.0% received antiplateletagents and 7.6% did not receive antithrombotic treatment. At the 2-year follow-up, 70.5% remained on dabigatran.Conclusions: Data from the GLORIA-AF Phase II registry showed that in nonvalvular AF, NOACs have been highly adopted in clinicalpractice, becoming more frequently prescribed than VKAs. Worldwide, however, a large proportion of patients have remainedundertreated.
No takes yet. Share an insight, caveat, or question.
Dubner et al. (2020) conducted an observational in Non-valvular atrial fibrillation (n=15,308). Dabigatran was evaluated on Incidence of stroke (per 100 person-years) (95% CI 0.48-0.87). In patients with newly diagnosed non-valvular atrial fibrillation, dabigatran treatment demonstrated sustained safety and effectiveness over 2 years, with a stroke incidence of 0.65 per 100 person-years.
Synapse has enriched 10 related papers. Consider them for comparative context: